H. Lundbeck A/S- (HLUYY) Downgraded by Zacks Investment Research to Hold
Zacks Investment Research cut shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) from a buy rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Shares of H. Lundbeck A/S- (OTCMKTS HLUYY) opened at $51.24 on Wednesday. The stock has a market cap of $10,115.61, a PE ratio of 21.17, a PEG ratio of 0.93 and a beta of 0.17. H. Lundbeck A/S- has a 1 year low of $40.70 and a 1 year high of $66.67. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.13 and a current ratio of 1.36.
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.